Biolase
BIOL
BIOL was delisted on the 18th of June, 2024.
34 hedge funds and large institutions have $40.1M invested in Biolase in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 0 closing their positions.
1,445% more capital inflows, than outflows
Capital inflows: $10.1M | Capital outflows: $653K
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
10% more funds holding
Funds holding: 31 → 34 (+3)
8.79% more ownership
Funds ownership: 33.61% → 42.4% (+8.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Camber Capital Management
Boston,
Massachusetts
|
+$8.45M |
| 2 |
Oracle Investment Management
Greenwich,
Connecticut
|
+$633K |
| 3 |
Granite Investment Partners
El Segundo,
California
|
+$613K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$218K |
| 5 |
Renaissance Technologies
New York
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
-$534K |
| 2 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
-$59.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$39.6K |
| 4 |
Goldman Sachs
New York
|
-$19.8K |
BIOL Hedge Fund Activity: Q4 2016 in Review
34 of the 4,009 institutional investors tracked by Wall St. Rank reported a position in Biolase (BIOL) for Q4 2016, worth a combined $40.1M — up 7.1% from $37.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BIOL positions and 0 closed out — a net gain of 3 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $8.45M. The largest seller was Consonance Capital Management, cutting an estimated $534K.
- 34 institutional investors held Biolase (BIOL) as of Q4 2016, up from 31 in Q3 2016.
- Funds reported $40.1M of Biolase stock for Q4 2016, up 7.1% quarter-over-quarter.
- 3 funds opened new Biolase positions in Q4 2016 and 0 closed out, a net change of +3 holders.
- The largest Biolase buyer in Q4 2016 was Camber Capital Management, an estimated $8.45M added.
- The largest Biolase seller in Q4 2016 was Consonance Capital Management, an estimated $534K sold.
Based on aggregated 13F filings for Q4 2016.